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Abstract
Background: Microglia are the principal cells involved in the innate immune response in the CNS. Activated
microglia produce a number of proinflammatory cytokines implicated in neurotoxicity but they also are a major
source of anti-inflammatory cytokines, antiviral proteins and growth factors. Therefore, an immune therapy aiming
at suppressing the proinflammatory phenotype while enhancing the anti-inflammatory, growth promoting
phenotype would be of great benefit. In the current study, we tested the hypothesis that interferon regulatory
factor 3 (IRF3), a transcription factor required for the induction of IFNb following TLR3 or TLR4 activation, is critical
to the microglial phenotype change from proinflammatory to anti-inflammatory, and that this phenotype change
can be greatly facilitated by IRF3 gene transfer.
Methods: Cultures of primary human fetal microglia were transduced with IRF3 using recombinant adenovirus
(Ad-IRF3) and subjected to microarray analysis, real-time PCR, immunoblotting and ELISA to determine
inflammatory gene expression. Two different types of immune stimuli were tested, the TLR ligands, poly IC (PIC)
and LPS, and the proinflammatory cytokines, IL-1/IFNg. In addition, the role of the PI3K/Akt pathway was examined
by use of a pharmacological inhibitor, LY294002.
Results: Our results show that Ad-IRF3 suppressed proinflammatory genes (IL-1a, IL-1b, TNFa, IL-6, IL-8 and CXCL1)
and enhanced anti-inflammatory genes (IL-1 receptor antagonist, IL-10 and IFNb) in microglia, regardless of the cell
stimuli applied. Furthermore, Ad-IRF3 activated Akt, and LY294002 reversed the effects of Ad-IRF3 on microglial
inflammatory gene expression. pAkt was critical in LPS- or PIC-induced production of IL-10 and IL-1ra. Significantly,
microglial IFNb protein production was also dependent on pAkt and required both Ad-IRF3 and immunological
stimuli (PIC > IL-1/IFNg). pAkt played much less prominent and variable roles in microglial proinflammatory gene
expression. This anti-inflammatory promoting role of PI3K/Akt appeared to be specific to microglia, since astrocyte
proinflammatory gene expression (as well as IFNb expression) required PI3K/Akt.
Conclusions: Our results show a novel anti-inflammatory role for the PI3K/Akt signaling pathway in microglia. They
further suggest that IRF3 gene therapy could facilitate the microglial phenotype switch from proinflammatory ("M1-
like”) to anti-inflammatory and immunomodulatory ("M2-like”), in part, by augmenting the level of pAkt.
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Innate immune pathways are early responses important
for pathogen control and are activated by specific recep-
tors recognizing pathogen- or danger-associated molecu-
lar patterns [1-5]. Microglia are the key cell type involved
in innate immune responses in the CNS [6-8]. The prop-
erties of microglia that contribute to this phenotype
include the presence of cell surface receptors that render
them highly reactive to a variety of innate and adaptive
immunological stimuli [9-11]. Microglial cells bear all
known TLRs, as well as phagocytic receptors, purinergic
receptors, class I and class II MHC antigens and co-sti-
mulatory molecules. Microglia in vivo reacts almost
immediately to the pathogen/danger signals by increased
motility of their processes and by upregulating innate
inflammatory gene expression. Although microglial acti-
vation has conventionally been linked to inflammation
and neurotoxicity (M1, “classically” activated macrophage
phenotype), we now know that microglial activation does
not always lead to neurodegeneration, as microglia can
also generate neuronal growth factors, as well as anti-
inflammatory cytokines (M2, “alternatively” activated
macrophage phenotype) contributing to neuroprotection
[6,12,13]. In addition to microglia, astrocytes can also
participate in the CNS innate inflammatory response
including antiviral immunity [14]. Studies also indicate
that neurons in vivo and in vitro possess pattern recogni-
tion receptors, and can respond to dsRNA by activation
of the innate immune signaling pathways including the
production of IFNb [15].
Interferon regulatory factor 3 (IRF3) is a 53 kDa tran-
scription factor crucial in the non-MyD88, TRIF path-
way of TLR signaling following activation of the TLR3
or TLR4 [16-19]. Phosphorylation of critical C-terminal
serine residues represents the single most important
physiological mechanism of activating IRF3. Following
phosphorylation, IRF3 dimerizes and translocates to the
nucleus, where DNA binding and transcriptional activa-
tion of target genes occur. In addition to TLRs, IRF3 is
also activated by the cytosolic dsRNA receptors (RIG-I-
like receptors), which constitute the primary receptors
utilized by most viruses. IRF3 activated by various
receptors, in concert with NF-B and the MAP kinases,
transactivates the IFNb gene, as well as several addi-
tional primary IRF3-dependent genes such as IP-10
(CXCL10), Rantes (CCL5), IFN-stimulated gene 56
(ISG56, aka IFN-induced protein with tetratricopeptide
repeats 1, IFIT1) and arginase II [18]. IFNb then acts in
an autocrine and paracrine manner to amplify the
downstream cascades of ISG synthesis including IFNa.
Studies in vitro show that IRF3 plays an indispensible
role in innate antiviral immunity including in microglia
and astrocytes [14,20,21]. In addition, IRF3 is critical in
neuroprotection mediated by LPS preconditioning [22],
as well as in limiting injury in experimental autoimmune
encephalomyelitis, an animal model of multiple sclerosis.
IRF3 is also implicated as a tumor suppressor gene [23].
Despite many known biological functions of IRF3, lit-
tle is known about the regulation of expression of IRF3
under normal or pathological conditions. Most cells
constitutively express IRF3 in vitro, but whether the
amount is sufficient to trigger effective antiviral or
immunoregulatory function is not known. Our immuno-
histochemistry study demonstrates that IRF3 expression
is highly cell type-specific, with most epithelial cells
showing high levels of expression and mesodermally-
derived cells showing low levels of expression. In the
CNS, IRF3 expression is detectable in ependymal cells
and choroid plexus, with little or no expression in the
brain parenchyma (Tarassishin et al., Antiviral and anti-
inflammatory mechanisms of the innate immune tran-
scription factor IRF3, submitted). In Sendai virus- or
HIV-infected cells in vitro, IRF3 can undergo proteaso-
mal degradation, a mechanism adopted by virus to avoid
cellular antiviral responses [24,25]. In the current study,
we used primary human microglial cells in culture to
test the hypothesis that IRF3 is a critical regulator of
microglial cytokine and chemokine expression and that
increasing microglial IRF3 protein expression by adeno-
virus-mediated gene transfer can alter the microglial
activation phenotype from proinflammatory to anti-
inflammatory or immunoregulatory, which we termed
“M1-like” and “M2-like”, respectively (see Discussion).
Methods
Microglial culture
Human CNS cell cultures were prepared from human
fetal abortuses as described with minor modifications
[26]. All tissue collection was approved by the Albert
Einstein College of Medicine Institutional Review Board.
Written consent was obtained from the participants of
the study. A copy of the consent is available for review
by the Editor-in-Chief of this journal. Primary mixed
CNS cultures were prepared by enzymatic and mechani-
cal dissociation of the cerebralt i s s u ef o l l o w e db yf i l t r a -
tion through nylon meshes of 230- and 130-μpore sizes.
Single cell suspension was plated at 1-10 × 10
6 cells per
ml in DMEM (Cellgro, now ThermoFisher Scientific)
supplemented with 10% FBS (Gemini Bio-products,
Woodland, CA), penicillin (100 U/ml), streptomycin
(100 μg/ml) and fungizone (0.25 μg/ml) (complete med-
ium) for 2 weeks, and then microglial cells were col-
lected by aspiration of the culture medium. Monolayers
of microglia were prepared in 60-mm tissue culture
dishes at 1 × 10
6 cells per 3 ml medium or in 96-well
tissue culture plates at 4 × 10
4 per 0.1 ml medium. Four
to eighteen hours later, cultures were washed to remove
non-adherent cells (neurons and astrocytes). Microglial
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+
cells.
Adenoviral vectors
Ad-IRF3 was created with pCMV-BL wildtype IRF3
plasmid (gift of John Hiscott, McGill University, Mon-
treal) and human serotype 5 recombinant adenovirus
(Adeno-X expression System 1) from BD Biosciences
following the manufacturer’sp r o t o c o l .I R F 3w i l d - t y p e
(WT) IRF3-expressing adenovirus was constructed by
first excising from pCMV-BL cDNA corresponding to
WT IRF3 at the EcoRV and XhoI sites. The insert was
cloned into the EcoRV and XhoI sites in pBluescript,
then excised using XbaIa n dKpnI. cDNA was subse-
q u e n t l yl i g a t e di n t ot h ep S h u t t l ev e c t o r( B DB i o s -
ciences). cDNA was excised according to the
manufacturer’si n s t r u c t i o n sw i t hP I - SceIa n dI - CeuI,
then cloned into the BD-AdenoX vector. A PacI-
digested linear piece of DNA containing the cDNA of
WT IRF3 along with the adenovirus genome was trans-
fected into HEK293 cells. At later times, supernatants
were tested for production of recombinant adenovirus
and expanded in culture. Ad-IRF3 does not contain a
reporter gene. Adenovirus containing the GFP gene
(Ad-GFP) and the lacZ gene (Ad-b-gal) were obtained
from Dr. Mario Stevenson, University of Massachusetts,
and Dr. Mark J. Czaja, Albert Einstein College of Medi-
cine, respectively. All recombinant adenoviral vectors
were amplified and purified using the service of the
Gene Therapy Core of Albert Einstein College of
Medicine.
Adenovirus-mediated gene transfer and cell stimulation
We examined human microglia for their gene expression
and cell signaling profiles following IRF3 (or control GFP
or b-gal) overexpression using adenovirus-mediated gene
transfer [27,28]. Cell transduction with serial dilutions of
the viral vectors demonstrated that approximately 70-
90% of cells were transduced after 48 h of adenoviral
infection at 500 multiplicity of infection (not shown),
similar to astrocytes [29]. A representative western blot
analysis of IRF3 protein expression in control, Ad-GFP
and Ad-IRF3 transduced microglial cultures is shown in
Figure 1. Cultures that were pre-incubated with adeno-
virus for 48 h were then activated with cytokines (IL-1b
and IFNg) or the TLR ligands poly IC (PIC) or LPS for an
additional 30 min to 72 h, as specified in individual
experiments. LPS and poly IC (PIC) were purchased from
S i g m a - A l d r i c h( S t .L o u i s ,M O ) .R e c o m b i n a n th u m a n
IFN- (specific activity, 1 ng = 20 U) and IL-1b were pur-
chased from Peprotech (Rocky Hill, NJ). Cultures were
treated with PIC at 10 μg/ml, LPS at 100 ng/ml or cyto-
kines at 10 ng/ml. For PI3K/Akt inhibition, cells were
pre-treated with LY294002 at 10 μMo n eh o u rp r i o rt o
cell stimulation with TLR ligands or cytokines. In all
experiments, culture medium was changed a low serum
medium (DMEM + 0.5% FBS) immediately before cell
stimulation.
Western blot analysis
Western blot analysis was performed as previously
described [14] with minor modifications. Briefly, cell
cultures in 60 mm dishes were scraped into lysis buffer
( P B Sp l u sp r o t e a s ei n h i b i t o r sf r o mS i g m a )a tv a r i o u s
time points. Thirty to fifty micrograms of protein was
separated by 10% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and then transferred to polyvinyli-
dene difluoride membrane. The blots were blocked in
PBS-0.1% Tween-20 containing 5% nonfat milk and
then incubated with antibodies at 4°C for 16 h. Primary
antibodies were against p-Akt (Ser 473), Akt, p-ERK and
p-JNK (Cell Signaling, Danvers, MA) and applied at a
dilution of 1:250 for all. The secondary antibody was
either horseradish peroxidase-conjugated anti-mouse or
anti-rabbit IgG (Pierce Biotechnology, Rockford, IL) and
w a su s e da t1 : 1 , 0 0 0f o r1ha tr o o mt e m p e r a t u r e( R T ) .
Signals were developed using enhanced chemilumines-
cence (Pierce Biotechnology, Rockford, IL). All blots
were reprobed with b-actin (Cell Signaling, Danvers,
MA) to control for protein loading. Densitometric ana-
lysis was performed using ImageJ software (NIH).
Enzyme-linked immunosorbent assay (ELISA)
IFNb levels were determined with VeriKine-HS Human
IFNb Serum ELISA kit (sensitivity: 2.3-150 pg/ml) from
PBL Interferon Source (Piscataway, NJ), according to
the manufacturer’s protocol. Luminex Multiplex ELISA
was performed with a customized kit according to the
manufacturer’s protocol (Millipore Corp. Billerica, MA).
IL-1b, TNFa, IL-6, IL-8, IL-10, IL-1ra and IP-10 ELISAs
were performed using the antibody pairs purchased
from the R&D Systems (Minneapolis, MN). Briefly, poly-
styrene 96-well plates (Nunc) were pre-coated overnight
at RT with specific capture Ab, then blocked with 1%
BSA in buffer A (PBS plus 0.1% Tween 20) for 1 h at
RT. The plates were then incubated with standard cyto-
kine dilutions or cell culture media for 2 h at RT,
washed with buffer A, and incubated with the biotiny-
lated detection Ab for 2 h at RT. After the second wash,
t h ep l a t e sw e r ei n c u b a t e dw i th HRP-streptavidin for 20
min at RT and washed again. The signal was developed
after addition of 3,3’,5,5’-tetramethylbenzidine-peroxi-
dase EIA kit (Bio-Rad) for 4-5 min and the reaction was
stopped by 1 M H2SO4. Microplate reader (Dynex Tech-
nologies) was used to detect the signals with 450 nm
and correction at 530 nm. The samples were diluted
until the values fell within the linear range of each
ELISA detection.
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Quantitative real-time reverse transcription-PCR (Q-
PCR) was performed as described previously [14,27,29].
Initial microglial experiments including both porphobili-
nogen deaminase (PBDA) and GAPDH as housekeeping
genes showed that the results were very similar with
either gene as a control. Therefore, all subsequent
experiments were done with PBDA and all results were
calculated using PBDA as a control. Total RNA was
extracted with TRIzol (Invitrogen Life Technologies),
following the manufacturer’s instructions. PCR was per-
formed using a SYBR green PCR mix and conducted
with the ABI Prism 7900HT (Applied Biosystems). All
values were expressed as the increase relative to the
expression of PBDA. The median value of the replicates
for each sample was calculated and expressed as the
cycle threshold (CT; cycle number at which each PCR
reaches a predetermined fluorescence threshold, set
within the linear range of all reactions). ΔCT was calcu-
lated as CT of endogenous control gene (PBDA) minus
CT of target gene in each sample. The relative amount
of target gene expression in each sample was then calcu-
lated as 2
ΔCT. Fold change was calculated by dividing
the value (2
ΔCT)o ft e s ts a m p l eb yt h ev a l u e( 2
ΔCT )o f
control sample (control = 1). TaqMan PCR was per-
formed with miR-155 primers according to the manu-
facturer’s protocol (Applied Biosystems).
Microarray analysis
Highly enriched microglial cultures were subjected to
microarray analysis using the Illumina platform. Briefly,
for each total RNA sample, linear amplification and bio-
tin-labeling of total RNA (500 ng) were carried out
using the Illumina TotalPrep RNA Amplification Kit
Figure 1 Expression IRF3 in human microglia. Microglial cultures were treated with medium alone (Ctr) or infected with Ad-GFP or Ad-IRF3
for 48 h, then analyzed by SDS-PAGE and western blotting for (total) IRF3, as described in the Methods.
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ome expression analysis was carried out by hybridization
of amplified RNA to an Illumina HumanHT-12 v3
Expression BeadChip (Illumina Inc., San Diego, CA).
With this beadchip, we interrogated greater than 48,000
probes per sample, targeting genes and known alterna-
tive splice variants from the RefSeq database release 17
and UniGene build 188. Controls for each RNA sample
(greater than 1000 bead types) confirmed sample RNA
quality, labeling reaction success, hybridization strin-
gency, and signal generation. All expression data were
quantile normalized and background-subtracted prior to
analysis using BeadStudio software (Illumina Inc.).
Statistical Analysis
For multiple comparisons, one-way ANOVA with Bon-
ferroni post test was performed. For comparison of two
groups, Student’s t-test was used. Fold induction or
inhibition by Ad-IRF3 from multiple experiments was
compared to control (Ad-GFP) using single sample t-
test. P values < 0.05 were considered significant. All sta-
tistics were performed using GraphPad Prism 5.0
software.
Results
Adenovirus-mediated IRF3 gene transfer alters the gene
expression profile of cultured human microglia
Our previous studies have suggested that over-expres-
sion of IRF3 by adenovirus-mediated gene transfer (Ad-
IRF3) might suppress microglial proinflammatory cyto-
kine expression while increasing anti-inflammatory and
antiviral gene expression [21]. In this study, we systema-
tically examined the changes in microglial gene expres-
sion following exposure to Ad-IRF3.
Cultures of primary human fetal microglia were
infected with recombinant Ad-IRF3 or the control ade-
novirus (Ad-GFP or Ad-b-gal) for 48 h as previously
described, and then further treated with inflammatory
stimuli (LPS, PIC or IL-1b/IFNg) for an additional 6 h -
24 h. Gene expression was examined by microarray ana-
lysis with the Illumina HumanHT-12 v3 Expression
BeadChip, or by real-time PCR, and protein expression
was examined by ELISA.
Representative data from microarray analyses are
shown in Table 1 for PIC-stimulated microglia and
Table 2 for IL-1/IFNg-stimulated microglia. Entire
microarray data sets are available as Supplementary
Material (Additional Files 1 and 2). In PIC-treated cul-
tures, IRF3-enhanced genes included IFNb, IL-29 (IFNl,
“type III IFN”) [30,31], IRF7, an inducible transcription
factor which synergizes with IRF3 [21,32], many ISGs
(not shown, see Supplemental Materials), TLR7, a TLR
shown to mediate antiviral and anti-inflammatory func-
tions in myeloid cells [33], and IL-10 receptor.
Intriguingly, IL-1a and IL-1ra, as well as the IL-12
family cytokines IL-23 and IL-27 [34] were differentially
regulated, showing increase in IL-1ra and IL-27 and
decrease in IL-1a/b and IL-23 (Table 1). These results
suggest that Ad-IRF3 can suppress the Th1/Th17 activa-
tion pathway and promote the Th2 pathway in
microglia.
Similar trends were observed in IL-1/IFNg-treated
microglial cultures (Table 2), i.e., downregulation of
proinflammatory cytokine genes such as IL-1a,I L - 1 b,
IL-8 and CXCL1 (GROa), but upregulation of anti-
inflammatory genes, antiviral genes and ISGs, such as
IL-1ra, IL-10, IL-10 receptor, IFNb,I F I T 1 ,I R F 7 ,s u p -
pressor of cytokine signaling 1 (SOCS1) and IL-27
(Table 2).
The microarray data show that microglial inflamma-
tory and antiviral genes are differentially regulated in
the presence of increased IRF3 protein expression, and
Table 1 Microarray studies of microglia transduced with
Ad-IRF3 or Ad-b-gal and stimulated with poly IC (PIC)
Gene Ratio
(IRF3/b-gal)
Difference in expression
(IRF3 minus b-gal)
IFNB(IFNb) 61.0 3863
IRF7 2.3 702
IL-1A (IL-1a) 0.22 -1413
IL-1RN (IL-1ra) 2.3 10836
IL-27 7.2 1291
IL-29 (IFN lambda) 75.0 231
IL-10RA (IL-10Ra) 3.3 954
IL-23 (p19) 0.47 -372
TLR7 2.2 813
Human fetal microglia were transduced with adenovirus (Ad-IRF3 or Ad-b-gal)
and further treated with the TLR3 ligand PIC for 16 h. Microarray was
performed using the Illumina platform.
Table 2 Microarray studies of microglia transduced with
Ad-IRF3 or Ad-GFP and stimulated with IL-1/IFNg
Gene Ratio
(IRF3/GFP)
Difference in expression
(IRF3 minus GFP)
IFNB (IFNb) 3.5 418
IRF7 2.3 1441
IFIT1 11.2 4464
SOCS1 2.6 776
IL-1A (IL-1a) 0.2 -708
IL-1B (IL-1b) 0.1 -4738
IL-1RN (IL-1ra) 6.4 2211
IL-10 1.9 364
IL-10RA (IL-10R) 2.4 1145
IL-27 1.8 250
IL-8 0.3 -15409
CXCL1 0.5 -167
Human fetal microglia were transduced with adenovirus for 2 days and
further treated with IL-1/IFNg for 16 h. Microarray was performed using the
Illumina platform.
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used (TLR ligands vs. proinflammatory cytokines).
Q-PCR validation of the Ad-IRF3 effects in microglial
inflammatory gene expression
We also employed Q-PCR to examine microglial gene
expression following exposure to Ad-IRF3. Figure 2
shows a typical experiment in which microglial cultures
derived from a single case were tested in six different
conditions: uninfected (Ctr), Ad-GFP-infected or Ad-
IRF3-infected, each with or without treatment with IL-
1/IFNg. Selected genes were examined based on the
microarray data, and the results showed that antiviral
and anti-inflammatory genes such as IFNb,I F I T 1a n d
IL-1ra were robustly upregulated by Ad-IRF3, and
proinflammatory genes such as IL-1b,I L - 8a n dT N F a
were downregulated by Ad-IRF3.
Q-PCR validation of the Ad-IRF3 effects in multiple
microglial cases
We have analyzed data from microglial cultures derived
from multiple donors in order to determine whether the
Ad-IRF3 effects are significant across many cases. Q-
PCR data were compiled from several microglial cases
treated with IL-1/IFNg and grouped into significantly
upregulated and downregulated genes, based on single
sample t-test. Ad-IRF3-upregulated genes are shown in
Figure 3A as ratios of gene expression in Ad-IRF3 cul-
ture to Ad-GFP culture in a log 10 scale. Ad-IRF3-
downregulated genes are shown in Figure 3B as % inhi-
bition, calculated by 100 × [1 - Ad-IRF3/Ad-GFP].
These results once again confirm that the two groups of
genes ("M1-like” and “M2-like”) are differentially regu-
lated by Ad-IRF3 in microglia.
Ad-IRF3 effects on microglial cytokine protein production
We next performed Luminex multiplex beads-based
protein analyses of IL-1/IFNg-stimulated microglia to
determine whether the Ad-IRF3-induced mRNA
changes are reflected at the protein level. We found
that IFNa2 and IL-1ra were increased while IL-1a and
TNFa were decreased by Ad-IRF3 (not shown). We
next expanded the study to compare the responses to
different stimuli (IL-1/IFNg, IL-1 alone, and LPS) in the
same microglial cases, and examined the production of
IL-1b, IL-1ra, IL-8 and IP-10 by individual ELISA (Fig-
ure 4). The results show that the amounts of proinflam-
matory cytokines such as IL-1b and IL-8 were markedly
decreased by Ad-IRF3, while the amounts of IL-1ra and
IP-10 (a known IRF3-dependent gene) [18,35] were
increased. These results confirm that Ad-IRF3 differen-
tially regulates microglial cytokine production, regard-
less of the types of stimuli applied (TLR ligands vs. IL-
1/IFNg).
Figure 2 Microglial genes that are upregulated (A) or downregulated (B) by Ad-IRF3 (Q-PCR). Primary human microglial cultures were
exposed to medium alone (Ctr), Ad-GFP (GFP) or Ad-IRF3 (IRF3) at 500 multiplicity of infection (moi) for 48 h, then stimulated with IL-1b and
IFNg at 10 ng/ml each for 16 h. Q-PCR analysis was performed using PBDA as a control. Y-axis denote fold changes calculated as described in
the Methods section, then normalized to the control level (without cytokine treatment). Note varying Y-axis scales. All samples were tested in
triplicate, and p-values were calculated by t-test (GFP vs. IRF3) using GraphPad Prism 5. * p < 0.05, ** p < 0.01, *** p < 0.001.
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treated with IL-1b/IFNg, and then Q-PCR analysis was performed as described in Figure 2 legend. Data were generated from 5-6 different
microglial cases, with each symbol representing a different case. (A) Genes upregulated by IRF3: fold changes in mRNA were calculated as
described in the Methods. Fold induction by Ad-IRF3 over Ad-GFP was expressed in a log scale (0.1 = no induction). (B) Genes downregulated
by IRF3. Y-axis denotes % inhibition by IRF3 calculated using the formula, 100 × [1 - Ad-IRF3/Ad-GFP]. In both A and B, p-values were generated
using single sample t-test (GraphPad Prism 5): * p < 0.05, ** p < 0.01, *** p < 0.001.
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In order to determine the mechanism by which Ad-
IRF3 mediates its effects on microglial cytokine expres-
sion, we examined cell signaling pathways altered by
Ad-IRF3 by western blot analysis. Three different cases
of microglial cultures were transduced with Ad-IRF3
or Ad-GFP (or neither, Ctr) for 48 h, and were sub-
jected to western blot analysis for p-Akt, p-Erk, p-Jnk,
and total Akt. Figure 5A demonstrates a representative
western blot and Figure 5B demonstrates densitometric
analysis normalized to the control level (Ctr = 1) from
three microglial cases. The results show that the levels
of p-Akt (Ser 473) increased in the presence of Ad-
IRF3, whereas those of p-Erk or p-Jnk were
unchanged.
Role of the PI3K/Akt pathway in Ad-IRF3-mediated
modulation of microglial gene expression
In order to determine whether pAkt contributed to Ad-
IRF3-mediated modulation of microglial gene expres-
sion, we employed a pharmacological inhibitor of PI3K,
LY294002. Microglial cultures were transduced with Ad-
IRF3 or Ad-GFP then stimulated with IL-1/IFNg in the
presence or absence of LY294002, as described in the
Methods. The results were examined by microarray
( F i g u r e6 A )a n da l s ob yQ - P C R( F i g u r e6 Ba n d6 C ) .I n
Figure 6A, gene expression ratios (Ad-IRF3 vs. Ad-GFP)
were expressed as % change, in which “0” represents no
change (IRF3/GFP = 1), + 100% represents two-fold
increase (IRF3/GFP = 2), and -50% represents 50% inhi-
bition (IRF3/GFP = 0.5). The results showed that the
Figure 4 Ad-IRF3 modulated microglial cytokine production (ELISA). Microglia were grown in 96-well plates and left uninfected (Ctr) or
infected with Ad-GFP or Ad-IRF3 for 48 h, and treated with IL-1b/IFNg (10 ng/ml each), IL-1b alone (10 ng/ml) or LPS (100 ng/ml) for 24 h.
Culture supernatants (IL-1ra, IP-10, and IL-8) or cell lysates (IL-1b) were analyzed for cytokine levels by ELISA as described in the Methods section.
All samples were tested in triplicate, and p-value was calculated by t-test (GFP vs. IRF3). * p < 0.05, ** p < 0.01, ***p < 0.001.
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expression of the two groups of genes, i.e., suppression
of Ad-IRF3-induced genes (IL-1ra, IFNb, IL-10R and
SOCS1) and increase of Ad-IRF3-inhibited genes
(CXCL1, IL-8, IL-1a,a n dI L - 1 b). The complete micro-
array data set is available as Supplemental Material
(Additional File 2).
These results are validated by Q-PCR. Figure 6B and
6C demonstrate Q-PCR data derived from several
microglial cases, shown as normalized values (cytokines
a l o n e=1 ) .T h e yc o n f i r mt h at LY inhibited Ad-IRF3-
upregulated genes (IFNb, IFIT1, IL-1ra and IL-10) while
increasing Ad-IRF3-inhibited genes (IL-8, CXCL1,
TNFa,a n dI L - 1 b). However, the effect of LY on IL-1b
mRNA expression was not significant, reflecting the
results obtained with microarray (see Figure 6A). Taken
together, these results demonstrate that the PI3K/Akt
pathway significantly contributes to the differential gene
regulation induced by Ad-IRF3 in microglia.
The role of the PI3K/Akt pathway in microglial
inflammatory gene expression
Because our data suggest a major role of PI3K/Akt in
Ad-IRF3-mediated immune modulation, we next exam-
ined the effect of LY294002 on microglial cytokine gene
induction by TLR activation or IL-1/IFNg.M i c r o g l i a
were stimulated with LPS, PIC or IL-1/IFNg in the pre-
sence or absence of LY294002 and the expression of
selected cytokine genes was examined by Q-PCR and
E L I S A .S h o w ni nF i g u r e7a r er e s u l t sf r o mm u l t i p l e
microglial cases, normalized to the values induced by
LPS, PIC or IL-1/IFNg alone. They show that the PI3K/
Akt pathway is involved in LPS- or PIC-mediated induc-
tion of anti-inflammatory cytokine genes (IL-10 and IL-
1ra), but that it had little or no effect on proinflamma-
tory cytokine mRNA expression (IL-1b,T N F a, IL-6 and
IL-8). Interestingly, LY294002 suppressed IL-1b protein
production, although it had no significant effect on IL-
1b mRNA. As noted before [21], human microglia
responded remarkably similarly to LPS or PIC. The
effects of LY294002 on cytokines induced by IL-1/IFNg
were different from those observed using TLR ligands
(Figure 7A and 7B). LY294002 had no significant effects
on anti-inflammatory gene expression, but it had signifi-
cant stimulatory effects on proinflammatory gene
expression (TNFa,I L - 8 ) ,w i t hn oc h a n g ei nI L - 1 b
mRNA levels (see below for ELISA data).
Since these data suggest a possible stimulus-dependent
role of PI3K in microglial inflammatory gene induction,
we next compared PIC and IL-1/IFNg as stimuli in the
Figure 5 Ad-IRF3 activates pAkt in human microglia. (A) Microglial cultures were infected (or not) with Ad-GFP or Ad-IRF3 for 48 h, then
analyzed by SDS-PAGE and western blotting for p-Akt (Ser 473), p-Erk, p-Jnk and total Akt as described in the Methods section. (B) Densitometry
was performed with ImageJ and the ratios of pAkt to total Akt were calculated from 3 different microglial cases. * p < 0.05 by t-test (GFP vs.
IRF3).
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Page 9 of 18Figure 6 The effect of the PI3K/Akt inhibitor on Ad-IRF3-mediated changes in microglial gene expression. Microglial cells were left
uninfected (Ctr) or infected with Ad-GFP or Ad-IRF3 for 48 h. The cells were then pre-treated with LY294002 (10 μM) for 1 h followed by
stimulation with IL-1b and IFNg for an additional 16 h. (A) Microarray analysis was performed using the Illumina platform, and the data are
presented as % change (Ad-IRF3 over Ad-GFP) as described in the Results section. The data show that LY294002 reversed the effect of Ad-IRF3
in microglial inflammatory gene expression, showing suppression of IRF3-enhanced genes and enhancement of IRF3-suppressed genes. (B, C) Q-
PCR confirmation of the microarray data (B: IRF3-enhanced genes, C: IRF3-suppressed genes). Q-PCR analysis was performed using PBDA as an
internal control as described in Methods. At least 3 different cases were tested in each experiment. All data were normalized to the level in Ad-
GFP culture (= 1).
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Page 10 of 18Figure 7 The effect of LY294002 on TLR3/4- or IL-1/IFNg-induced microglial inflammatory gene expression. Microglial cells were pre-
treated with LY294002 for 1 h and then stimulated with LPS (100 ng/ml), PIC (10 μg/ml), or IL-1b and IFNg (10 ng/ml) for 16 h. Q-PCR (left
column: A, C and E) and ELISA (right column: B and D) were performed as described above. All values were normalized to those obtained in
cultures stimulated with LPS, PIC or IL-1/IFNg without LY294002 (= 1). At least 3 cases were analyzed for each experiment, and statistics were
performed using t-test comparing values with vs. without LY294002.
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Page 11 of 18same microglial case. The role of Ad-IRF3 was also
determined. Microglia were transduced with Ad-IRF3 or
Ad-GFP (or neither) and further stimulated with PIC or
IL-1/IFNg in the presence or absence of LY294002. The
production of IFNb,I L - 8a n dI L - 1 b was determined by
ELISA (Figure 8).
Measurement of IFNb using a highly sensitive ELISA
kit (detection range 2.3 - 150 pg/ml) demonstrated that
neither PIC nor IL-1/IFNg (without Ad-IRF3) induced
detectable amounts of IFNb from microglia (Figure 8A).
IFNb was produced when cells were exposed to both
Ad-IRF3 and immune stimuli (PIC >> IL-1/IFNg,n o t e
different Y-axis scales). Furthermore, IFNb production
was almost completely inhibited by LY294002. In con-
trast, LY294002 had no effect on PIC-induced IL-8 pro-
tein production (similar to mRNA data in Figure 7C),
but it increased IL-8 production by IL-1/IFNg (similar
to mRNA data in Figure 7E), suggesting a suppressive
role of PI3K/Akt in IL-1/IFNg-induced IL-8 expression
(Figure 8B). Furthermore, LY294002 suppressed PIC-
induced IL-1b protein production (similar to data in
Figure 7D), but it increased IL-1/IFNg-induced IL-1b
protein production (similar to its effect on IL-8 protein).
The effect of LY294002 in the presence of Ad-IRF3
resembled the results obtained by microarray and Q-
PCR in Figure 6. For all three cytokines, PIC provided a
stronger stimulus than IL-1/IFNg for microglia (Figure
8, note different Y-axis scales).
Together, our experiments with LY294002 show that
the PI3K/Akt pathway plays a crucial role in the induc-
tion of key anti-inflammatory and immunomodulatory
g e n e ss u c ha sI L - 1 r a ,I L - 1 0a n dI F N b from microglia.
They also show that boosting the amount of IRF3 pro-
tein in microglia is necessary for adequate IFNb
response upon further stimulation with TLR ligands or
cytokines. The PI3K/Akt pathway plays dual roles in
proinflammatory cytokine production from microglia,
depending on the nature of the stimuli used to induce
cytokines: it plays a suppressive role when cytokines (IL-
1/IFNg) are used as inducing stimuli, but shows little
effects when the TLR3/4 ligands (LPS or PIC) are used
as stimuli. One exception was TLR3/4-induced IL-1b
protein expression, which was enhanced by PI3K/Akt
presumably by post-transcriptional modification, since
mRNA levels did not change.
Role of PI3K/Akt in astrocyte cytokine production
In order to determine whether the “anti-inflammatory”
role of pAkt was unique to microglia, we examined
astrocyte responses to LY294002. Primary human fetal
astrocytes were prepared and stimulated as previously
described [14,26,29]. The cultures were stimulated IL-1/
IFNg or PIC, with or without LY294002, essentially in
the same manner described for microglia. Q-PCR or
ELISA was performed to determine the expression of
“proinflammatory” (IL-8, TNFa, and CXCL1) genes or
IFNb gene. TaqMan Q-PCR was performed to deter-
mine the expression of mic r o R N A ,m i R - 1 5 5 ,a s
described [29]. The results show that PI3K has a very
different role in astrocytes, as LY294002 suppresses all
proinflammatory genes, IFNb,a sw e l la st h ep r o i n f l a m -
matory microRNA, miR-155 (Figure 9). These results
are consistent with the role of PI3K/Akt upstream of
NF-B or MAPK in the astrocyte signal transduction
cascades.
Summary and hypothesis
Our results show that the PI3K/Akt pathway plays a
crucial role in the induction of key cytokines of anti-
inflammatory and immunomodulatory nature from
microglia (i.e., IL-1ra, IL-10 and IFNb), regardless of the
stimuli applied (Figure 10). (A) In IL-1/IFNg-stimulated
microglia, while large amounts of proinflammatory cyto-
kines are produced, little or no anti-inflammatory or
immunoregulatory cytokines are produced. The PI3K/
Akt pathway functions as an endogenous inhibitor of
proinflammatory gene expression, possibly by suppres-
sing proinflammatory factors such as miR-155. (B)
Transduction of microglia with Ad-IRF3 robustly
increases the production of anti-inflammatory and
immunoregulatory genes upon stimulation with IL-1/
IFNg, while decreasing the production of proinflamma-
tory genes. This effect is presumably mediated by
increased activation of Akt by Ad-IRF3. (C, D) In TLR3/
4-activated microglia, Akt is activated downstream of
TRIF, which critically contributes to the induction of
anti-inflammatory and immunoregulatory genes such as
IFNb [ 3 6 ] .H o w e v e r ,i nn o r m a lm i c r o g l i a ,t h el o w
amount of IRF3 protein precludes effective IFNb pro-
duction (C). Following transduction with Ad-IRF3, a
positive feedback loop between pAkt and pIRF3
becomes established which then amplifies induction of
anti-inflammatory and immunoregulatory genes and
suppression of proinflammatory genes through multiple
mechanisms (D). For simplicity, we refer to the two phe-
notypes of microglia as “M1-like” and “M2-like”, respec-
tively (see Discussion).
Discussion
Our study was designed to investigate the role of IRF3
transgene expression in microglial inflammatory activa-
tion. Our data in primary human microglial cultures
show that adenovirus-mediated IRF3 transgene expres-
sion changes the microglial cytokine profile from a
proinflammatory phenotype to an anti-inflammatory or
immunoregulatory phenotype. Specifically, the expres-
sion of IL-1ra, IL-10 and IFNb was markedly induced,
while the expression of many proinflammatory cytokines
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Page 12 of 18Figure 8 The effect of LY294002 on PIC-, IL-1/IFNg-, or Ad-IRF3-induced microglial cytokine expression (ELISA). Microglia cultures were
grown in 96-well plates, infected (or not) with Ad-GFP or Ad-IRF3 for 48 h. Cultures were then pretreated with LY (10 μM) for 1 h before
stimulation with PIC (10 μg/ml) or IL-1b/IFNg (10 ng/ml each) for an additional 24 h. Culture supernatants or cell lysates were analyzed for IFNb
(A), IL-8 (B) and IL-1b (C) by ELISA as described in the Methods section. All samples were tested in triplicates, and p-values was determined by t-
test (with vs. without LY294002). * p < 0.05, ** p < 0.01.
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Page 13 of 18such as IL-1 was suppressed consistently and signifi-
cantly. Additional suppressed proinflammatory genes
included TNFa, IL-6 and IL-8 and CXCL1.
We refer to the microglial cytokine expression profile
changes described here as “M1-like” or “M2-like”,f o l -
lowing the general scheme of M1 and M2 activation
phenotypes developed in mouse macrophages and sub-
sequently adopted to describe microglial activation
phenotypes [6]. There are a number of differences
between human microglia and murine microglia. For
example, although iNOS is a prototypic marker of M1-
activated murine microglia, it is not expressed by
human microglia [37]. In addition, human microglia do
not express certain Th1 or Th2 cytokines such as IFNg
or IL-4. There might also be additional differences
between macrophages and microglia. For these and
Figure 9 The effect of the PI3K pathway inhibitor LY294002 on astrocyte cytokine and chemokine expression.P r i m a r yh u m a nf e t a l
astrocytes were stimulated with IL-1/IFNg or PIC, with or without LY294002, essentially in the same manner described for microglia. Q-PCR (A)o r
ELISA (B) was performed to determine the expression of “proinflammatory” (IL-8, TNFa, and CXCL1) genes or IFNb gene. (C) TaqMan Q-PCR was
performed to determine the expression of microRNA, miR-155. All values were normalized to those without LY294002 and t-test was used to
determine p values. * p < 0.05, ** p < 0.01, *** p < 0.001.
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Page 14 of 18other reasons, we refer to the microglial phenotypes
described here as “M1-like” or “M2-like”.
Importantly, we note these changes regardless of the
types of immunological stimuli applied (TLR3/4 ligands
as well as IL-1/IFNg, to mimic non-infectious neuroin-
flammatory conditions). The observed effects of IRF3
transgene in the suppression of proinflammatory cyto-
kine genes is novel and points to a mechanism by which
IRF3 influences other signaling pathways. In addition,
we have obtained novel findings that indicate that the
PI3K pathway plays a predominantly anti-inflammatory
role in microglial activation. It played a particularly
potent role in the induction of anti-inflammatory and
immunoregulatory cytokines such as IL-10, IL-1ra and
IFNb. These results together suggest that activation of
the PI3K/Akt pathway (via Ad-IRF3, for example) in
microglia can lead to the resolution of inflammation
and promotion of repair under neuroinflammatory con-
ditions [38-40].
The PI3K/Akt pathway is unique for its multitudes of
roles in transcriptional regulation of cytokine genes.
Employing a pharmacological inhibitor, we show that
the PI3K/Akt pathway is involved in both the suppres-
sion (of “M1-like”) and the enhancement (of “M2-like”)
of cytokine genes in IRF3-transduced microglia. One
might speculate that the impressive amounts of suppres-
sion of proinflammatory genesi nA d - I R F 3 - t r a n s d u c e d
cells are at least in part secondary to the induction of
anti-inflammatory and immunoregulatory genes, as IL-
1ra, IL-10 and IFNb each can function as a suppressor
of proinflammatory cytokine expression. For example,
we have previously shown that recombinant IFNb sup-
presses IL-1 and increases IL-1ra production in human
microglia [41]. IFNb also induces certain chemokines
[42]. Microarray analysis of human peripheral blood
mononuclear cells (PBMCs) exposed to IFNb demon-
strated that distinct sets of genes are upregulated or
downregulated by IFNb, the latter including IL-1b,
Figure 10 Schematic representation of the proposed molecular events that are affected by Ad-IRF3 in microglia.A d - I R F 3 ,t h r o u g h
suppression of “M1-like” gene expression and over-expression of “M2-like” gene (IFNb, IL-10 and IL-1ra) expression in microglia, can suppress
proinflammatory cytokine cascades that are implicated in neurodegeneration. pAkt plays a major role in regulating microglial inflammatory gene
expression. In Ad-IRF3-transduced microglia, a positive feedback mechanism between pAkt and pIRF3 could induce a state that is dominated by
the “M2-like” cytokines. See text for details.
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Page 15 of 18CXCL1, and IL-8 [43]. Therefore, IFNb most certainly
played a role as an intermediary cytokine that mediated
the effect of Ad-IRF3 in our system. Additional cyto-
kines that might have played a role in our system
include IFNa, as well as type III IFNs. Type III IFNs are
newly discovered interferons that share a number of
similarities with type I IFNs including their mechanism
of induction and their biological activities [30]. One
might also speculate that the opposite effects of
LY294002 on the two groups of genes can be best (and
most simply) explained by the prominent role played by
PI3K/Akt on microglial “M2-like” cytokine induction.
Furthermore, we show that PI3K/Akt might play a dif-
ferent role in proinflammatory gene expression (without
Ad-IRF3) depending on the stimulus applied, as that
induced by IL-1/IFNg was suppressed by PI3K/Akt,
while little changes were noted in PIC-stimulated micro-
glia, and PIC-induced IL-1b production was even
increased. We also note that although IL-1 expression
was consistently and potently suppressed by Ad-IRF3
transduction in microglia, its expression appeared to be
least affected by the PI3K inhibitor. Therefore, multiple
mechanisms must exist that mediate the effects of Ad-
IRF3 on microglial cytokine expression. Additionally, the
adenoviral vector may have evoked some elements of
inflammatory activation in microglia and that this may
have created conditions that contributed to the effects
seen 48 h after adenovirus infection. Our results with
LY294002 are reminiscent of those obtained in mouse
macrophages deficient in phosphatase and tensin homo-
logue (PTEN), a negative regulator of Akt, which
showed similar differential regulation of cytokines, i.e.,
decrease in TNFa/IL-6 and increase in IL-10 [44] sup-
porting the dual role played by PI3K/Akt in Ad-IRF3-
transduced microglial cytokine expression. Our results
demonstrating a pivotal role of pAkt in IFNb produc-
tion is also in line with another study of murine
macrophages which demonstrated a critical role of
pAkt in TLR-induced IRF3 activation and IFNb
expression downstream of TRIF signaling [36]. The
a n t i - i n f l a m m a t o r yr o l eo fA k ti nm o u s em a c r o p h a g e s
has been most convincingly demonstrated in a study in
which Akt1-deficient mice injected with LPS showed
increases in proinflammatory cytokine production
compared to wildtype mice [45]. In the latter study,
the effect of Akt1 was attributed in part to its suppres-
sion of microRNA-155 (miR-155) expression. miR-155
is a proinflammatory microRNA that increases cyto-
kine production by targeting specific mRNAs such as
suppressor of cytokine signaling (SOCS1) mRNA
[29,46,47]. These results are interesting, since miR-155
was significantly elevated by IL-1/IFNg in human
microglia (data not shown), suggesting that suppres-
sion of miR-155 may be the mechanism by which Akt
modulated “M1-like” cytokines in IL-1/IFNg-stimulated
microglia (Figure 10A).
The role of the PI3K/Akt pathway in cytokine produc-
tion is also cell-type specific. In human astrocytes, we
see that LY294002 suppresses both “M1-like” (TNFa
and IL-8, for example) and “M2-like” cytokine (IFNb)
expression induced by PIC or IL-1/IFNg (Figure 9).
These results suggest that in astrocytes, Akt is activated
upstream of NF-B (and MAPK) following activation of
TLR3 or IL-1R. In addition, LY294002 suppresses miR-
155 expression in astrocytes, indicating a positive role
for PI3K/Akt in miR-155 expression in astrocytes (Fig-
ure 9). These results demonstrate that the PI3K/Akt
pathway plays a fundamentally different role in the
inflammatory activation of the two glial cell types (astro-
cytes vs. microglia). It is also possible that microglia and
astrocytes express different combinations of Akt iso-
forms, with each isoform having distinct immune regu-
latory functions. These are some of the topics that need
to be explored in future studies.
Our results suggest that in Ad-IRF3-transduced
microglia, a positive feed forward loop between Akt and
IRF3 might be established resulting in downmodulation
of inflammatory activation. For example, evidence sup-
ports that signaling through TRIF (TLR3 or TLR4) or
MyD88 (TLR4 or IL-1R) activates Akt [21] that is criti-
cal in the activation of IRF3 [28,36,48,49]. Furthermore,
Ad-IRF3 increases the level of pAkt, likely contributing
to increased activation of IRF3, in addition to increase
in total IRF3 (Figures 5 and 10). It is unclear how Ad-
IRF3 increases pAkt in microglia. We do not believe
this was mediated by IFNb because we do not see mea-
surable IFNb in cultures treated with Ad-IRF3 alone
(not shown). In addition, our previous studies showed
that while IFNb activates microglial NF-Ba n dM A P
kinases (ERK) immediately, IFNb (or IFNg) does not
activate Akt until later time points (6 h), indicating an
indirect mechanism of activation [21,50].
The major change that we see in IRF3-transduced
microglia is downmodulation of the IL-1 axis. IL-1 is a
non-redundant cytokine expressed primarily by micro-
glia and macrophages but also by T cells. Microglial IL-
1 is induced early after CNS insult and is capable of
activating downstream cytokine cascades, as well as
auto-amplification cascades [41,51]. In vitro,m i c r o g l i a l
IL-1 is induced by diverse types of stimuli [4,52] and
serves as a potent neurotoxin [53,54]. IL-1 is also crucial
in the Th17 differentiation of human T cells [55-57].
The amount of IL-1 signal transduction is primarily
determined by the relative abundance of the agonists
(IL-1a or IL-1b) and the antagonist (IL-1ra). The impor-
tance of IL-1ra in human biology has been elucidated in
recent discovery of an inflammatory disease caused by
homozygous deletion/mutations of the IL1RN locus
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Page 16 of 18[58-60]. A term DIRA (deficiency of the IL-1ra) has
been proposed to denote this life-threatening autoin-
flammatory disease caused by unopposed action of IL-1.
Of interest, IFNb and glatiramer acetate, disease-modify-
ing treatments for multiple sclerosis, are both known to
exert opposing effects on IL-1a/b and IL-1ra [41,61].
Therefore, the combined effects of IL-1 receptor antag-
onism and the robust increase in IL-10 and IFNb pro-
d u c t i o ni nA d - I R F 3 - t r a n s d u c e dm i c r o g l i ac o u l d
significantly alter the neuroimmune environment in
favor of resolution of inflammation and promotion of
repair. The data obtained in this study should be useful
in future development of therapeutic strategies aiming
at neuroinflammation.
Conclusions
In this study, we tested the hypothesis that upregulation
of IRF3 protein in primary human microglia by virus-
induced gene transfer could alter the microglial inflam-
matory activation phenotype from the proinflammatory
("M1-like”) to the anti-inflammatory and immunoregula-
tory ("M2-like”) phenotype. Our results indeed show that
IRF3-overexpressing microglia upregulate key anti-
inflammatory cytokines and downregulate proinflamma-
tory cytokines such as IL-1. We provide evidence that the
PI3K/Akt pathway plays an anti-inflammatory role in
microglia and that IRF3-mediated microglial phenotype
switch is associated with augmentation of Akt activation.
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Ad-IRF3 or Ad-GFP and stimulated with IL-1/IFNg with or without
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Table 2 and Figure 6A.
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